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Background: A cell line with transfected Wilms’ tumor pro-
tein 1 (WT1) is has been used for the preclinical evaluation of 
novel treatment strategies of WT1 immunotherapy for leuke-
mia due to the lack of appropriate murine leukemia cell line 
with endogenous WT1. However, silencing of the transgene 
occurs. Regarding the effects of hypomethylating agents 
(HMAs) on reactivation of silenced genes, HMAs are consid-
ered to be immune enhancers. Methods: We treated murine 
WT1- transfected C1498 (mWT1-C1498) with increasing 
doses of decitabine (DAC) and azacitidine (AZA) to analyze 
their effects on transgene reactivation. Results: DAC and 
AZA decreased the number of viable cells in a dose- or 
time-dependent manner. Quantification of WT1 mRNA level 
was analyzed by real-time polymerase chain reaction after 
mWT1-C1498 treated with increasing dose of HMA. DAC 
treatment for 48 h induced 1.4-, 14.6-, and 15.5-fold incre-
ment of WT1 mRNA level, compared to untreated sample, at 
0.1, 1, and 10μM, respectively. Further increment of WT1 
expression in the presence of 1 and 10μM DAC was evident 
at 72 h. AZA treatment also induced up-regulation of mRNA, 
but not to the same degree as with DAC treatment. The cor-
relation between the incremental increases in WT1 mRNA by 
DAC was confirmed by Western blot and concomitant 
down-regulation of WT1 promoter methylation was revealed. 
Conclusion: The in vitro data show that HMA can induce re-
activation of WT1 transgene and that DAC is more effective, 
at least in mWT1-C1498 cells, which suggests that the com-
bination of DAC and mWT1-C1498 can be used for the de-
velopment of the experimental model of HMA-combined 
WT1 immunotherapy targeting leukemia.
[Immune Network 2012;12(2):58-65]
INTRODUCTION
Although  chemotherapy  and  allogeneic  hematopoietic  stem 
cell transplantation (allo-HSCT) are still the mainstays of ther-
apy  for  leukemia,  immunotherapy  is  one  of  the  alternative 
promising  treatment  options.  The  graft-versus-leukemia  ef-
fects induced by allo-HSCT or post-transplant donor lympho-
cyte  infusion  are  the  most  powerful  evidence  of  immuno-
logical eradication of leukemia, showing that allo-HSCT itself 
is  a  powerful  immunotherapy  (1).  Immunotherapeutic  ap-
proaches other than HSCT involve the immunization of pa-
tients with cancer antigen with the goal of stimulating anti-
gen-specific  cytotoxic  T  lymphocytes  (CTL)  or  the  adoptive 
transfer of ex-vivo generated cancer specific CTL that will rec-
ognize  and  kill  the  tumor.
    Among the various immunotherapeutic targets, Wilmsٗ tu-
mor protein 1 (WT1) was ranked first in a list of 75 cancer 
antigens in a recent report from National Cancer Institute pri-
oritization project (2,3). Also, WT1 is the most promising po-
tential target of leukemia as it is more abundant in leukemia 
cells than in normal hematopoietic cells (4,5) and seems to 
participate in leukemogenesis and may be necessary to main-
tain the viability of leukemia cells (6). Furthermore, WT1 is 
apparently immunogenic as shown by spontaneous immune 
responses in leukemic patients (7,8). A growing body of evi-Hypomethylation-induced Transgene Reactivation
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dence supports WT1 as a promising target for hematological 
malignancies,  and  various  clinical  trials  have  demonstrated 
the  feasibility  of  this  approach  (3,9-15).
    Regarding the wide applicability of WT1 immunotherapy, 
preclinical experiments using murine WT1-expressing leuke-
mia cell lines could lead to resolution of many of the critical 
issues for the development of clinical treatment strategies, of 
which usefulness is further strengthened by the similarity be-
tween murine and  human WT1 (16,17).  However,  none of 
the murine cell lines with endogenous WT1 expression are 
available, except the FBL3 cell line used for an earlier animal 
study  (18),  but  which  was  substituted  for  by  murine  WT1- 
transfected C1498 (mWT1-C1498) as FBL3 was too aggressive 
and  not  appropriate  for  immunotherapy  model.
    The  transgene  system  such  as  mWT1-C1498  provides  a 
convenient way for understanding the gene function and gen-
erating preclinical experimental models. However, expression 
levels  of  transgene  in  transfected  cells  often  declines  with 
time (19,20). The molecular basis of this gene silencing is not 
clearly understood but is thought to be associated with hyper-
methylation of transgene DNA (21,22), which is a similar way 
by which tumors escape immune reaction by editing tumor 
antigens or immune related genes. Although transgene silenc-
ing has generally been regarded as one of the major draw-
backs for experimental use, we assumed that this phenomen-
on was amenable to being adopted for the development of 
an  experimental  model  where  the  potential  role  of  hypo-
methylating agents (HMAs) for the reactivation of silenced tu-
mor antigen could be tested as an immune enhancer (23,24). 
    To test this possibility, the present study represents the first 
step to investigate the effects of decitabine (DAC) and azaciti-
dine (AZA)  on  transgene-containing  cell lines  and  silencing 
WT1 from the viewpoint of cell viability, WT1 expression lev-
el, and accompanying changes in methylation status induced 
b y  t h e  t w o  H M A s .
MATERIALS AND METHODS
Cell culture and drug treatment
mWT1-C1498  and  mock-transfected  C1498  (mock-C1498) 
were  kindly  provided  by  Dr.  H.  Sugiyama  (University  of 
Osaka,  Japan).  Cells  were  grown  in  DMEM  (Dulbeccoٗs 
modified Eagleٗs medium) (GIBCO, Grand Island, NY, USA) 
supplemented  with  10%  fetal  bovine  serum  (FBS;  GIBCO) 
and antibiotics (Invitrogen, Carlsbad, CA, USA) in a humidi-
fied  atmosphere  containing  5%  CO2 a t  3 7
oC.
  D A C  a n d  A Z A  w e r e  p u r c h a s e d  f r o m  S i g m a - A l d r i c h  ( S t .  
Louis,  MO, USA). Stock solutions of DAC (40μM) and AZA 
(400μM) were prepared in dimethyl sulfoxide (DMSO) and 
stored at −70
oC. The stock solutions were further diluted in 
DMSO  (0.1∼10μM; ＜0.1%  DMSO  final  concentration)  for 
cell  culture  experiments.
Cell viability assay
To  evaluate  the  growth  inhibitory  effect  of  HMA  on  C1498 
c e l l s  w i t h  o r  w i t h o u t  W T 1  t r a n s g e n e ,  a n  M T S  a s s a y  u s i n g  
CellTiter 96
Ⓡ AQueous One Solution Cell Proliferation (Pro-
mega, Madison, WI, USA) was done according to the manu-
factureٗs  instruction.  Briefly,  cells  were  seeded  in  96-well 
plates  at  a  density  of  1×10
4/100μl  of  culture  medium  for 
24 hours to reach exponential phase of growth when various 
concentrations  of  HMA  or  vehicle  control  were  added. 
Following 72 hours incubation, reagent was added into each 
well containing the samples and the plate was incubated for 
1 hour at 37
oC in a humidified, 5% CO2 atmosphere. Absor-
bance at 490 nm was recorded using a 96-well spectropho-
tometer (Molecular Devices, Sunnyvale, CA, USA). The doses 
that inhibited 50% proliferation (IC50) were analyzed by the 
median-effect method (CalcuSyn software; Biosoft, Cambridge, 
UK).
RNA extraction and cDNA synthesis
RNA from the cells was extracted by TRIZOL reagent (Invitro-
gen) and recovered from the aqueous phase by an isopropyl 
alcohol  precipitation.  RNA  was  re-suspended  in  diethylpyr-
ocarbonate-treated water and quantitated by spectrophotome-
try (UV/VIS Spectrophotometer ND-100; Nanodrop, Wilming-
ton, DE, USA) and reverse cDNA transcription was performed 
on 1μg of total RNA. cDNA was synthesized in 20μl of a 
solution  containing  random  hexameric  primers  (Promega) 
with the use of AMV reverse transcriptase (Promega), 5X RT 
buffer  (Promega),  10  mM  dNTP  mixture  (Promega),  and 
RNase inhibitor (Promega). The mixtures were incubated at 
20
oC for 10 min and subsequently incubated at 42
oC for 80 
min,  and  denatured  by  heating  at  95
oC  for  5  min.
Reverse transcription-polymerase chain reaction (RT- 
PCR) and real-time PCR
RT-PCR  was  performed  on  1μl  of  cDNA  using  GoTaq
Ⓡ 
Green Master Mix (Promega). RT-PCR conditions for all genes 
were as follows: 1 cycle at 95
oC for 2 min followed by 35 
cycles  at 95
oC  for  10  sec,  60
oC  for  5  sec,  and  72
oC  for  10 Hypomethylation-induced Transgene Reactivation
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sec.  WT1  and  glyceraldehyde-3-phosphate  dehydrogenase 
( G A P D H )  e x p r e s s i o n  l e v e l s  w e r e  d e t e r m i n e d  b y  v i s u a l i z i n g  
DNA bands on SYBR
Ⓡ Safe DNA gel stain (Invitrogen) stained 
1.5% agarose gels. WT1 mRNA expression levels were quanti-
fied  by  real-time  PCR  using  SYBR  Green  assay  (Bio-Rad, 
Hercules, CA, USA) with Bio-CFX96 (Bio-Rad). The WT1 pri-
mers for RT-PCR or real-time PCR were aWT1 sense (5'-taca-
gatgcatagccggaagc-3')  and  WT1  antisense  (5'-cctgtgtgtctccttt-
ggtg-3'). GADPH primer sets used for normalizing the quan-
tity of WT1 were GAPDH sense (5'-ggtgtgaacggatttggccgtatt-3') 
and  GAPDH  antisense  (5'-ggccttgactgtgccgttgaattt-3').  Real- 
time PCR was performed using CFX96
TM on 1μl cDNA in 2X 
iQTM SYBR Green Supermix (Bio-Rad) under following con-
ditions: 1 cycle at 95
oC for 10 min followed by 40 cycles at 
95
oC for 10 sec, 60
oC for 5 sec, and 72
oC for 10 sec. Samples 
were measured in triplicate. The resulting data were analyzed 
with CFX96 manager software (Bio-Rad). The amount of tar-
get gene was normalized to the endogenous level of GAPDH. 
This was done to obtain the relative threshold cycle (△Ct) 
in relation to the Ct of the control gene to measure the rela-
tive  expression  level  (2
-△△Ct)  o f  t h e  t a r g e t  g e n e .
Evaluation of WT1 protein level using Western analysis
Mock and mWT1-C1498 cells treated with DAC or vehicle for 
48 h and 72 h were lysed by RIPA buffer (Thermo Scientific, 
Rockford, IL, USA) with protease inhibitor cocktail (Thermo 
Scientific). Proteins were separated by 10% sodium dodecyl 
sulfate-polyacrylamide  gel  electrophoresis  (SDS-PAGE)  and 
transferred  to  nitrocellulose  transfer  membranes  (Whatman 
GmbH, Dassel, Germany). Membranes were incubated with 
anti-WT1  (Santa  Cruz  Biotechnology,  Santa  Cruz,  CA,  USA) 
and anti-β-actin (Abcam, Cambridge, MA, USA) antibodies. 
X-ray  image  of  the  membrane  was  developed  using  a 
SuperSignal
Ⓡ West Pico Chemiluminescent Substrate (Thermo 
Scientific).
Evaluation of methylation status of WT1 promoter
Genomic DNA was prepared from mWT1-C1498 cells treated 
with or without DAC. Bisulfite conversion of genomic DNA 
was carried out using an EZ Methylation kit (Zymo Research, 
O r a n g e ,  C A ,  U S A )  a s  f o l l o w s :  5 0 0  n g  o f  D N A  w a s  s o d i u m 
bisulfite treated, denatured at 98
oC for 10 min, bisulfite con-
verted at 64
oC for 2.5 hr, and then desulfonated and eluted 
using a column preparation. Primer sequences of WT1 gene 
amplification conditions were sense (5'-cgggacgagcagcgcgc-3') 
and  antisense  (5'-gtcgatcgacgtcatgtcgtcg-3').  Pyrosequencing 
was  performed  using  PyroMark
Ⓡ  CpG  assay  (Mm_Wt1_05_ 
PM) (QIAGEN, Hilden, Germany) reagents and the PSQ 96MA 
machine (Biotage, Uppsala, Sweden).  CpG  site  methylation 
analysis was performed with the Pyro Q-CpG 1.0.9 software 
( B i o t a g e ) ,  a n d  f o r  e a c h  C p G  s i t e  a  m e t h y l a t i o n  p e r c e n t a g e  
was calculated. Mock-C1498 cells treated with vehicle were 
used  as  negative  control  for  methylation-specific  assays. 
Busifite DNA (QIAGEN) universally methylated for all genes 
w a s  u s e d  a s  a  p o s i t i v e  c o n t r o l  f o r  m e t h y l a t e d  a l l e l e s  ( d a t a  
not  shown).
Statistical analysis
The  experimental  results  are p r e s e n t e d  a s  m e a n ± s t a n d a r d  
deviation  from  triplicate  samples  of  three  independent 
experiments.  Statistical  analysis  was  performed  using  Prism 
version 5 (GraphPad Software, San Diego, CA, USA). p＜0.05 
was  considered  to  be  statistically  significant.
RESULTS
Effects of HMA on cell viability
We examined the effects of DAC and AZA on the growth and 
survival of mock- and mWT1-C1498 cells, which were eval-
uated with MTS assay after culture with the drugs at a dose 
of  0,  0.1,  0.5,  1,  5,  and  10μM for 24 h, 48 h, and 72 h. 
During 24 h culture, cell viability did not change with increas-
ing concentrations of DAC in both cell lines. Meanwhile, AZA 
decreased cell viability in a dose-dependent manner. On the 
long-term  culture  (48  and  72  h),  it  was  revealed  that  DAC 
decreased the number of viable cells in both cell lines in a 
dose- and time-dependent manner, while AZA decreased cell 
viability in a dose-dependent manner rather than a time-de-
pendent manner (Fig. 1). When the IC50 of the drugs at 48 
and 72 h were compared, AZA showed higher IC50 compared 
to DAC in mWT1-C1498 cells at both time points, but vulner-
ability of mock-C1498 to the drugs were different according 
to exposure time. Generally, mWT1-C1498 cells were likely 
to be more susceptible to DAC than mock-C1498 cells when 
treated for 48 and 72 h (Table I). These results indicate that 
both HMA have a significant effect on cell viability at 48 h 
or longer treatment at doses ≥5μM, but that exposure time 
was  more  important  in  DAC  treatment.
Effect of HMA on mRNA expression of WT1
Initial screening by RT-PCR indicated the absence and pres-
ence of WT1 in mock- and mWT1-C1498, respectively, and Hypomethylation-induced Transgene Reactivation
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Figure 1. Effects of HMA on cell 
viability. In all cases, cell viability 
was measured using MTS assay as 
described. (A) C1498 cells were 
cultured with increasing concen-
trations of HMA for 24 h, 48 h, and
72 h. mock-C1498 cells treated with
0.1∼10μM DAC for 24 h up to 72
h. (B) mWT1-C1498 cells treated 
with 0.1∼10μM DAC for 24 h up 
to 72 h. (C) mock-C1498 cells 
treated with 0.1∼10μM AZA for 
24 h up to 72 h. (D) mWT1-C1498
cells treated with 0.1∼10μM AZA 
for 24 h up to 72 h. Samples were 
measured in triplicates.




48 h 72 h 48 h 72 h
mock-C1498 9.07±4.59 3.57±2.15 6.13±3.47 3.86±1.56
mWT1-C1498 2.83±1.4 1.41±0.38 4.44±1.61 1.89±1.89
Values are presented as mean±SD of three independent experiments.
treatment with DAC could change WT1 mRNA expression lev-
el in mWT1-C1498 without non-specific response in the con-
trol cell line (Fig. 2A). Quantification of WT1 mRNA level was 
further  analyzed  by  real-time  PCR  after  mWT1-C1498  cells 
were  treated  with  0,  0.1,  1,  and  10μM DAC and AZA  for 
48 h and 72 h. DAC treatment for 48 h induced 1.4-, 14.6-, 
and 15.5-fold increment of WT1 mRNA level compared to un-
treated sample at 0.1, 1, and 10μM, respectively, with the 
latter change being statistically significant (Fig. 2B). Further 
increment of WT1 expression level at 1 and 10μM was ob-
served with a 72 h treatment with DAC. AZA treatment also 
induced 1.48-, 3.99-, and 18.94-fold WT1 gene re-expression 
a t  0 . 1 ,  1 ,  a n d  1 0 μM,  respectively,  for  48  h  (Fig.  2C). 
Contrary to DAC, further treatment with AZA up to 72 h re-
sulted  in  the  down-regulation  of  WT1  mRNA.  Collectively, 
DAC was more potent compared to AZA in inducing re-ex-
pression of WT1 transgene at a dose of 1 and 10μM, and 
longer  treatment  with  DAC  induced  higher  expression.  On 
the basis of these results, DAC was selected for the following 
experiments  using  mWT1-C1498.
Effect of DAC on protein expression level of WT1
Western blot analysis was performed on mWT1-C1498 cells 
treated with DAC at various doses (0.1, 1, 10μM) for 48 and 
72 h. When a total of 100μg protein for each lane were load-
ed, a visible band was not observed in untreated samples or 
samples treated with 0.1μM DAC, but strong bands were ob-
served at higher doses of 1 and 10μM, which correlated with Hypomethylation-induced Transgene Reactivation
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Figure 2. (A) HMA mediates in-
duction of WT1 in C1498 cells in a 
time- and dose-dependent manner 
by RT-PCR results. (B, C) Expression
levels of WT1 mRNA were deter-
mined by real-time PCR in untreated
and HMA treated mWT1-C1498 
cells at 48 h and 72 h. Shown are 
the mean mRNA values normalized
to GAPDH from at least three ex-
periments. Error bars indicate the 
standard deviation. Data are ex-
pressed as mean±SD; *p＜0.05, 
***p<0.001.
Figure 3. DAC mediates induction of WT1 in mWT1-C1498 cells in 
a time-dependent manner. Expression of WT1 protein in mock-C1498
and mWT1-C1498 cells at 48 h and 72 h treated with 0, 0.1, 1, and
10μM DAC.
Figure 4. Dose-dependent hypomethylation induction by DAC in 
mWT1-C1498 cell lines. (A) A representative methylation analysis of 
four CpG-sites of the WT1 promoter using pyrosequencing. (B) 
Average percentage for each sample is displayed as bar graphs. Data
are expressed as mean±SD; ***p＜0.001.
the  changes  in  mRNA  level  by  real-time  PCR  (Fig.  3).
Hypomethylation of CpG islands in mWT1-C1498 
accompanied with WT1 gene transcriptional activity
We  then  assessed  whether  methylation  patterns  of  CpG  is-
lands  were  accompanied  with  transcriptional  activity  of  the 
WT1 gene. mWT1-C1498 cells were treated with DAC at 0.1, 
1, and 10μM for 48 h and 72 h, and their methylation status 
was determined by pyrosequencing and compared to vehicle 
control. After 48 h DAC treatment, mean methylation status 
of four sites were 94.8%, 93.5%, 78.48%, and 60.75% at 0, 
0.1,  1,  and  10μM,  respectively.  Differences  of  methylation 
status between control and 1 or 10μM were statistically sig-
nificant  and  correlated  with  the  WT1  up-regulation  at  the 
m R N A  a n d  p r o t e i n  l e v e l s  ( F i g .  4 ) .  F u r t h e r  t r e a t m e n t  u p  t o  
72 h also showed the decrement of methylation status, but 
i t  w a s  n o t  d i f f e r e n t  f r o m  t h o s e  o f  4 8  h .Hypomethylation-induced Transgene Reactivation
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DISCUSSION
Recent advances in immunotherapy have opened the possibil-
ities of further eradication of post-chemotherapy residual leu-
kemia by targeting leukemia-associated antigens of WT1 (25). 
One  strategy  to  enhance  anti-tumor  immune  reaction  is  to 
combine chemotherapy with immunotherapy, so called che-
moimmunotherapy (26), which clearly demonstrates that che-
motherapeutic agents can synergize with and enhance T cell 
response in pre-clinical and clinical studies (27,28). These ap-
proaches seem to be helpful in overcoming immune escape 
mechanism of leukemia with which the phenotypic changes 
of the leukemic cells characterized by the down-regulation or 
disappearance  of  tumor  antigen,  human  leukocyte  antigen 
( H L A ) ,  o r  c o - s t i m u l a t o r y  m o l e c u l e s  a r e  p a r t l y  i n v o l v e d .  I n  
line with this theoretical base, HMA are also considered ap-
propriate candidate agents for chemoimmunotherapy as they 
augment CTL response by inducing tumor antigens or HLA 
(29,30). As seen in solid tumors, induction of tumor antigens 
by  HMA  was  also  observed  in  hematological  malignancies 
(31).
  Two HMAs, DAC and AZA, belong to a class of cytosine 
analogues that inhibit DNA methylation and have shown clin-
ical efficacy in myelodysplastic syndrome and acute myeloge-
nous leukemia. In addition to their antineoplastic activity, re-
cent  evidence  suggested  that  HMA  can  modulate  important 
immune functions via epigenetic modifications (32,33), mak-
ing it an attractive candidate for pharmacologic manipulation 
of theimmunotherapy. Although epigenetic modulation of im-
mune function has been widely studied, measuring anti-WT1 
immune responses in leukemia in association with HMA has 
never been studied because of the lack of appropriate murine 
leukemia  cell  lines  and  available  animal  models.  WT1  ex-
pressing  solid  tumor  cell  lines  such  as  TRMP-C  were  alter-
natively used for preclinical animal experiments for the evalu-
ation of anti-WT1 immunology in patients with leukemia (34). 
    In pursuing a new experimental model, we performed in 
vitro  experiments  and  revealed  the  up-regulation  of  WT1 
transgene  expression  by  treating  mWT1-C1498  with  HMA, 
which  was  related  with  the  hypomethylation  of  transgene. 
We first evaluated the cytotoxicity of DAC and AZA on cell 
viability.  With  24  h  culture,  DAC  was  minimally  toxic  to 
mock-  and  mWT1-C1498  cells.  Meanwhile,  AZA  showed 
higher toxicity, especially at doses ≥5μM. However, longer 
incubation showed a trend of higher toxicity of DAC, espe-
cially  in  mWT1-C1498  cells  when  comparing  IC50 o f  t w o  
drugs at two time points. There was no differences in IC50 
between  the  two  cell  lines  in  AZA  treatment,  but  mWT1- 
C1498 cells were more vulnerable to DAC. When decreased 
cell growth by DAC was assessed in association with apopto-
sis,  the  drug  induced  apoptosis  in  dose-dependent  and 
time-dependent  manners,  similar  to  the  patterns  of  cell 
viability. Next, we analyzed the expression level of transgene. 
A  lower  dose  of  DAC  or  AZA  (0.1μM )  d i d  n o t  a f f e c t  t h e  
mRNA level of WT1, but higher doses of the drugs induced 
up-regulation of the gene level. Significant increment was ob-
served with DAC at 1.0 and 10μM, but only at 10μM for 
AZA. At these two dose levels, relative increment of mRNA 
was  prominent  in  DAC  treatment  in  the  comparison  with 
AZA,  whether  incubation  time  was  48  h  or  72  h,  showing 
higher efficiency of transgene reactivation of DAC. Of course, 
this  result  should  not  be  translated  to  indicate  that  DAC  is 
superior  to  AZA  in  up-regulating  silenced  tumor  antigens. 
Rather, differences in WT1 transgene reactivation in our study 
might be explained by the observation by Hollenbach et al. 
who suggested that the majority of genes regulated by AZA 
and  DAC  are  drug-specific as  they  show  distinctly  different 
effects in their actions on cell viability, protein synthesis, cell 
cycle,  and  gene  expression  (35).  We  also  observed  that 
up-regulation  of  WT1  transgene  was  accompanied  by  con-
comitant  down-regulation  of  methylation  status,  suggesting 
that  transgene  expression  could  be  regulated  by  the  epi-
genetic modifications marking on the promoter (36). Regard-
ing histone decetylation (HDAC) in addition to DNA methyl-
ation  is  the  major  epigenetic  changes  associated  with  gene 
suppression (37), further studies to combine HMA with HDAC 
inhibitor could be pursued to modulate transgene silencing.
    Our results suggest that treatment of mWT-C1498 cells with 
DAC can efficiently reactivate the silenced WT1 transgene by 
induction of DNA hypomethylation of the promoter region, 
w h ic h s ug g e st s th e  po ssi bi lit y  t ha t D A C c o ul d e n ha nc e  im-
mune reaction against silenced WT1 transgene in mWT-C1498 
cells. Further studies are needed to develop an animal model 
of  epigenetically  modulated  immunotherapy,  where  novel 
treatment  strategies  of  chemoimmunotherapy  targeting  WT1 
can  be  practically  investigated.
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